

12 January 2018

### **Resonance Health announces two new clinical trial contracts**

The Board of Resonance Health (ASX: RHT) announces that the Company has executed two multi-year contracts with pharmaceutical companies for undisclosed sums. Both trials are scheduled to commence in the first quarter of 2018, with the Company expanding its capabilities to provide Contract Research Organisation (CRO) services.

The first of the studies will evaluate the efficacy and safety of a potential new therapy to address patients with transfusion-dependent beta-thalassemia. The second will investigate the efficacy and safety of a new treatment for patients requiring regular blood transfusions.

Resonance Health is able to leverage its extensive distribution network to facilitate expeditious roll out of services to over twenty five existing customer sites for these trials. The Company looks forward to continuing its relationships with these prestigious hospitals throughout the US and globally, and welcoming eleven new sites as customers. Resonance Health has activated over four hundred hospital and private radiology sites globally throughout its 10 year history.

Further updates will be provided as work progresses.

Martin Blake

Chairman RHT

**For further information please contact:**

Alison Laws

Chief Business Development Officer, Resonance Health

E: [alisonl@resonancehealth.com](mailto:alisonl@resonancehealth.com) P: +61 (0)8 9286 5300